CTLA4 expression by Treg cells (28–31) and IL22 and IL17 production by ILC3 innate lymphocytes (32–35) have both been shown to prevent or limit the development of inflammatory bowel syndromes and particularly colitis in the LI. Here, IL17A is linked to colitis.